<p>格林威治生命科学公司（NASDAQ:GLSI - 获取免费报告）首席执行官 Snehal Patel 于 4 月 7 日星期一购买了 3,600 股该公司的股票。该股票的平均购买价格为每股 9.10 美元，总交易额为 32,760.00 美元。收购后，首席执行官现在拥有 5,561,602 股公司股票，价值 50,610,578.20 美元。此次交易使其持股比例增加了 0.06%。该收购在向证券交易委员会的备案中披露，相关文件可通过此链接获取。</p>
<p>获取 <strong>格林威治生命科学</strong> 的提醒：</p>
<p>Snehal Patel 最近还进行了以下交易：</p>
<ul>
<li>在 4 月 4 日星期五，Snehal Patel 购买了 5,500 股格林威治生命科学的股票。该股票的平均购买价格为每股 8.73 美元，总交易额为 48,015.00 美元。</li>
<li>在 1 月 10 日星期五，Snehal Patel 购买了 2,500 股格林威治生命科学的股票。该股票的平均购买价格为每股 12.51 美元，总价值为 31,275.00 美元。</li>
</ul>
<h2>格林威治生命科学股票上涨 0.3%</h2>
<p>在周二的交易时段，格林威治生命科学的股票上涨了 0.03 美元，达到 9.62 美元。该公司共交易了 13,852 股股票，而其平均交易量为 40,189 股。格林威治生命科学公司过去 12 个月的最低股价为 8.06 美元，最高股价为 18.75 美元。该股票的 50 日简单移动平均为 11.65 美元，200 日简单移动平均为 12.75 美元。该公司的市值为 1.2639 亿美元，市盈率为-12.02，贝塔值为 1.76。</p>
<h2>分析师评级变动</h2>
<p>另外，HC Wainwright 在 2 月 11 日的研究报告中重申了对格林威治生命科学的 “买入” 评级，并设定了 38.00 美元的目标价。</p>
<p><strong>阅读我们对 GLSI 的最新分析</strong></p>
<h2>格林威治生命科学的机构交易</h2>
<p>机构投资者和对冲基金最近买卖了该公司的股票。富国银行在第四季度将其在格林威治生命科学的持股比例提高了 54.8%。富国银行现在拥有 2,847 股该公司的股票，价值 32,000 美元，此前在该期间内又购买了 1,008 股。布朗兄弟哈里曼公司在第四季度收购了格林威治生命科学的新股份，价值约 45,000 美元。摩根大通在第四季度将其在格林威治生命科学的持股比例提高了 172.0%。摩根大通现在拥有 7,061 股该公司的股票，价值 79,000 美元，此前在上个季度又收购了 4,465 股。美国银行在第四季度将其在格林威治生命科学的持股比例提高了 22.3%。美国银行现在拥有 7,262 股该公司的股票，价值 82,000 美元，此前在该期间内又收购了 1,322 股。最后，巴克莱银行在第四季度将其在格林威治生命科学的持股比例提高了 12.7%。巴克莱银行现在拥有 9,648 股该公司的股票，价值 108,000 美元，此前在上个季度又购买了 1,088 股。机构投资者和对冲基金持有该公司 4.16% 的股票。</p>
<h2>关于格林威治生命科学</h2>
<p>（获取免费报告）</p>
<p>格林威治生命科学公司是一家临床阶段的生物制药公司，开发用于乳腺癌和其他 HER2/neu 表达癌症的新型癌症免疫疗法。其主要产品候选药物是 GP2，一种免疫疗法，目前正在进行 III 期临床试验，以防止曾接受手术的患者乳腺癌复发。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，胜过格林威治生命科学</li>
<li>什么是低市盈率，它对投资者意味着什么？</li>
<li>PayPal 股票：太便宜而无法忽视，太强大而无法错过</li>
<li>什么是分红成就者？简介</li>
<li>进展软件：在人工智能革命的推动下取得进展</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>英特尔 - 台湾半导体联盟推动复苏希望</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0xTSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0xTSQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在格林威治生命科学吗？</h2>
<p>在考虑格林威治生命科学之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而格林威治生命科学并不在名单上。</p>
<p>虽然格林威治生命科学目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

GLSI

<p>Greenwich LifeSciences, Inc. 首席执行官 Snehal Patel 以每股 9.10 美元的价格购买了 3,600 股公司股票，总计 32,760 美元。此次购买后，Patel 现在拥有 5,561,602 股，价值约 5060 万美元，持股比例增加了 0.06%。该股票最近交易价格为 9.62 美元，12 个月的价格区间为 8.06 美元至 18.75 美元。分析师 HC Wainwright 维持 “买入” 评级，目标价为 38 美元。机构投资者也增加了对该公司的持股，该公司专注于开发癌症免疫疗法</p>

<p>Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel purchased 3,600 shares of the firm's stock in a transaction on Monday, April 7th. The stock was bought at an average price of $9.10 per share, for a total transaction of $32,760.00. Following the acquisition, the chief executive officer now owns 5,561,602 shares in the company, valued at $50,610,578.20. The trade was a 0.06 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink.</p>
<div class="lb-trans"><p>格林威治生命科学公司（NASDAQ:GLSI - 获取免费报告）首席执行官 Snehal Patel 于 4 月 7 日星期一购买了 3,600 股该公司的股票。该股票的平均购买价格为每股 9.10 美元，总交易额为 32,760.00 美元。收购后，首席执行官现在拥有 5,561,602 股公司股票，价值 50,610,578.20 美元。此次交易使其持股比例增加了 0.06%。该收购在向证券交易委员会的备案中披露，相关文件可通过此链接获取。</p>
</div><p>Get <strong>Greenwich LifeSciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>格林威治生命科学</strong> 的提醒：</p>
</div><p>Snehal Patel also recently made the following trade(s):</p>
<div class="lb-trans"><p>Snehal Patel 最近还进行了以下交易：</p>
</div><ul>
<li>On Friday, April 4th, Snehal Patel bought 5,500 shares of Greenwich LifeSciences stock. The stock was purchased at an average price of $8.73 per share, for a total transaction of $48,015.00.</li>
<li>On Friday, January 10th, Snehal Patel purchased 2,500 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $12.51 per share, with a total value of $31,275.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 4 月 4 日星期五，Snehal Patel 购买了 5,500 股格林威治生命科学的股票。该股票的平均购买价格为每股 8.73 美元，总交易额为 48,015.00 美元。</li>
<li>在 1 月 10 日星期五，Snehal Patel 购买了 2,500 股格林威治生命科学的股票。该股票的平均购买价格为每股 12.51 美元，总价值为 31,275.00 美元。</li>
</ul>
</div><h2>Greenwich LifeSciences Stock Up 0.3 %</h2>
<div class="lb-trans"><h2>格林威治生命科学股票上涨 0.3%</h2>
</div><p>Shares of Greenwich LifeSciences stock traded up $0.03 during trading hours on Tuesday, hitting $9.62. 13,852 shares of the company's stock traded hands, compared to its average volume of 40,189. Greenwich LifeSciences, Inc. has a twelve month low of $8.06 and a twelve month high of $18.75. The stock has a 50 day simple moving average of $11.65 and a 200-day simple moving average of $12.75. The company has a market cap of $126.39 million, a PE ratio of -12.02 and a beta of 1.76.</p>
<div class="lb-trans"><p>在周二的交易时段，格林威治生命科学的股票上涨了 0.03 美元，达到 9.62 美元。该公司共交易了 13,852 股股票，而其平均交易量为 40,189 股。格林威治生命科学公司过去 12 个月的最低股价为 8.06 美元，最高股价为 18.75 美元。该股票的 50 日简单移动平均为 11.65 美元，200 日简单移动平均为 12.75 美元。该公司的市值为 1.2639 亿美元，市盈率为-12.02，贝塔值为 1.76。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>Separately, HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $38.00 price target on shares of Greenwich LifeSciences in a research report on Tuesday, February 11th.</p>
<div class="lb-trans"><p>另外，HC Wainwright 在 2 月 11 日的研究报告中重申了对格林威治生命科学的 “买入” 评级，并设定了 38.00 美元的目标价。</p>
</div><p><strong>Read Our Latest Analysis on GLSI</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 GLSI 的最新分析</strong></p>
</div><h2>Institutional Trading of Greenwich LifeSciences</h2>
<div class="lb-trans"><h2>格林威治生命科学的机构交易</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the company. Wells Fargo &amp; Company MN raised its holdings in shares of Greenwich LifeSciences by 54.8% during the fourth quarter. Wells Fargo &amp; Company MN now owns 2,847 shares of the company's stock worth $32,000 after purchasing an additional 1,008 shares during the period. Brown Brothers Harriman &amp; Co. acquired a new stake in Greenwich LifeSciences during the fourth quarter worth about $45,000. JPMorgan Chase &amp; Co. lifted its holdings in Greenwich LifeSciences by 172.0% in the fourth quarter. JPMorgan Chase &amp; Co. now owns 7,061 shares of the company's stock worth $79,000 after acquiring an additional 4,465 shares during the last quarter. Bank of America Corp DE boosted its stake in Greenwich LifeSciences by 22.3% in the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company's stock valued at $82,000 after acquiring an additional 1,322 shares during the period. Finally, Barclays PLC grew its holdings in shares of Greenwich LifeSciences by 12.7% during the fourth quarter. Barclays PLC now owns 9,648 shares of the company's stock valued at $108,000 after purchasing an additional 1,088 shares during the last quarter. Institutional investors and hedge funds own 4.16% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买卖了该公司的股票。富国银行在第四季度将其在格林威治生命科学的持股比例提高了 54.8%。富国银行现在拥有 2,847 股该公司的股票，价值 32,000 美元，此前在该期间内又购买了 1,008 股。布朗兄弟哈里曼公司在第四季度收购了格林威治生命科学的新股份，价值约 45,000 美元。摩根大通在第四季度将其在格林威治生命科学的持股比例提高了 172.0%。摩根大通现在拥有 7,061 股该公司的股票，价值 79,000 美元，此前在上个季度又收购了 4,465 股。美国银行在第四季度将其在格林威治生命科学的持股比例提高了 22.3%。美国银行现在拥有 7,262 股该公司的股票，价值 82,000 美元，此前在该期间内又收购了 1,322 股。最后，巴克莱银行在第四季度将其在格林威治生命科学的持股比例提高了 12.7%。巴克莱银行现在拥有 9,648 股该公司的股票，价值 108,000 美元，此前在上个季度又购买了 1,088 股。机构投资者和对冲基金持有该公司 4.16% 的股票。</p>
</div><h2>About Greenwich LifeSciences</h2>
<div class="lb-trans"><h2>关于格林威治生命科学</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.</p>
<div class="lb-trans"><p>格林威治生命科学公司是一家临床阶段的生物制药公司，开发用于乳腺癌和其他 HER2/neu 表达癌症的新型癌症免疫疗法。其主要产品候选药物是 GP2，一种免疫疗法，目前正在进行 III 期临床试验，以防止曾接受手术的患者乳腺癌复发。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Greenwich LifeSciences</li>
<li>What is a Low P/E Ratio and What Does it Tell Investors?</li>
<li>PayPal Stock: Too Cheap to Ignore, Too Strong to Miss</li>
<li>What Are Dividend Achievers? An Introduction</li>
<li>Progress Software: Making Progress Driven by the AI Revolution</li>
<li>What is the Dow Jones Industrial Average (DJIA)?</li>
<li>Intel-Taiwan Semiconductor Alliance Fuels Turnaround Hopes</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过格林威治生命科学</li>
<li>什么是低市盈率，它对投资者意味着什么？</li>
<li>PayPal 股票：太便宜而无法忽视，太强大而无法错过</li>
<li>什么是分红成就者？简介</li>
<li>进展软件：在人工智能革命的推动下取得进展</li>
<li>道琼斯工业平均指数（DJIA）是什么？</li>
<li>英特尔 - 台湾半导体联盟推动复苏希望</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0xTSQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=GLSI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Greenwich LifeSciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在格林威治生命科学吗？</h2>
</div><p>Before you consider Greenwich LifeSciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑格林威治生命科学之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Greenwich LifeSciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐，现在就买入，以便在更广泛的市场注意到之前……而格林威治生命科学并不在名单上。</p>
</div><p>While Greenwich LifeSciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然格林威治生命科学目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Greenwich LifeSciences, Inc.（纳斯达克股票代码：GLSI）的首席执行官收购了价值 32,760.00 美元的股票